DOCSLIB.ORG

Inositol Safety: Clinical Evidences

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Inositol Safety: Clinical Evidences European Review for Medical and Pharmacological Sciences 2011; 15: 931-936 Inositol safety: clinical evidences G. CARLOMAGNO, V. UNFER AGUNCO Obstetrics & Gynecology Center, Rome (Italy) Abstract. – Myo-inositol is a six carbon ent required by the human cells for the growth cyclitol that contains five equatorial and one axi- and survival in the culture. In humans and other al hydroxyl groups. Myo-inositol has been classi- species, Myo-inositol can be converted to either fied as an insulin sensitizing agent and it is L- or D-chiro-inositol by epimerases. Early stud- commonly used in the treatment of the Polycys- tic Ovary Syndrome (PCOS). However, despite ies showed that inositol urinary clearance was al- its wide clinical use, there is still scarce informa- tered in type 2 diabetes patients, the next step tion on the myo-inositol safety and/or side ef- was to link impaired inositol clearance with in- fects. The aim of the present review was to sum- sulin resistance (for a review see1). Because of marize and discuss available data on the myo-in- these properties, inositol have been classified as ositol safety both in non-clinical and clinical set- “insulin sensitizing agent”2. tings. The main outcome was that only the highest In the recent years, inositol has found more dose of myo-inositol (12 g/day) induced mild and more space in the reproductive clinical prac- gastrointestinal side effects such as nausea, fla- tice3-6. Indeed, since the main therapy for Poly- tus and diarrhea. The severity of side effects did cystic Ovary Syndrome (PCOS) is the use of in- not increase with the dosage. sulin sensitizing agent inositol is mainly use as a chronic treatment for this disease2,5,7,8. Further- Key Words: more, recently it was proposed as a preventing Myo-inositol, PCOS, Side effects, Dosage, NTDs. agent for folate-resistant neural tube defects (NTDs)9,10. The toxicity of Myo-inositol has not been di- rectly investigated. However, a number of studies have been conducted to investigate the efficacy of myo-inositol in preventing the pathological Introduction changes associated with experimental dia- betes11,12 (and other pathology models) and as a Myo-inositol (also known as inositol, hexahy- cancer chemoprevention agent13-16. The data of droxycyclohexane, or cis-1,2,3,5-trans-4,6-cyclo- these studies provide useful data for evaluating hexanehexol) is a six carbon cyclitol that con- the toxicity of myo-inositol. The relevant studies tains five equatorial hydroxyl groups and one in will be described and discussed hereafter. axial position. The main source of myo-inositol With the present review we aim to summarize is the diet, indeed it is found in a wide variety of some data that are availed in the literature in both foods such as whole grains, seeds, and fruits. non clinical and clinical settings. Myo-inositol can also be synthesized from glu- cose, the immediate precursor being fructose 6- Non Clinical Studies phosphate, which is converted to myo-inositol by Pugliese et al11 investigated the potential effect a cyclase. Myo-inositol is a precursor in the of myo-inositol on diabetes-induced vascular phosphatidylinositol cycle. It is a source of sever- functional changes. Myo-inositol was adminis- al second messengers including diacylgycerol, tered to diabetic rats as supplement in the diet, which regulates some members of the protein ki- ranging from 0.5, 1, or 2% (w/w). Vascular func- nase C family, inositol-1,4,5-triphosphate, which tional changes were evaluated by examining: (1) modifies intracellular calcium levels, and phos- 131I-labeled bovine serum albumin (BSA) perme- phatidylinositol-3,4,5-biphosphate, which is in- ation of vessels in multiple tissues, (2) glomeru- volved in the signal transduction. It is a compo- lar filtration rate (GFR), estimated as renal plas- nent of cell membranes and is an essential nutri- ma clearance of 57Co-labeled EDTA, (3) regional Corresponding Author: Gianfranco Carlomagno, Ph.D.; e-mail: [email protected] 931 G. Carlomagno, V. Unfer blood flows, measured with 15-microns 85Sr-la- chemical changes triggered by kainate-induced beled microspheres, and 4) endogenous albumin status epilepticus (SE) in rats. The effects of and IgG urinary excretion rates, quantified by ra- myo-inositol were investigated after both acute dial immunodiffusion assay. After 1 month of in- (1 day) and sub-acute (28 days) administration. duced-diabetes, 131I-BSA tissue clearance in- For the acute administration the study was per- creased significantly (2- to 4-fold) in the anterior formed on three different groups, (1) male Wistar uvea, choroid-sclera, retina, sciatic nerve, aorta, rats received intraperitoneal injection of kainic new granulation tissue, diaphragm, and kidney acid (10 mg/kg). Six hours following the treat- but was unchanged in skin, forelimb muscle, and ment, rats received myo-inositol 30 mg/kg, by in- heart. Myo-inositol-supplemented diets reduced jection; (2) rats received only 30 mg/kg myo-in- diabetes-induced increases in 131I-BSA clearance ositol (by injection); (3) rats treated with only (in a dose-dependent manner) in all tissues. saline as controls. However, only in new granulation tissue and di- For the sub-acute study also three different aphragm did the 2% myo-inositol diet complete- groups were analysed (1) rats were treated on ly normalize vascular albumin permeation. Dia- day 1 with kainate received twice a day myo-in- betes-induced increases in GFR and in urinary ositol for 28 days; (2) rats were not treated with albumin and IgG excretion were also substantial- kainate on day 1 and received myo-inositol for ly reduced or normalized by dietary myo-inositol 28 days; (3) rats were not treated with kainate supplements. Increased blood flow in anterior and received saline instead of myo-inositol as uvea, choroid-sclera, kidney, new granulation tis- controls. Changes in proteins expression in the sue, and skeletal muscle in streptozotocin-D hippocampus and neocortex, were evaluated. (STZ-D) rats also was substantially reduced or Proteins studied were: GLUR1, subunit of gluta- normalized by the 2% myo-inositol diet. Notably, mate receptors, calcium/calmodulin-dependent the Authors noted that myo-inositol had minimal protein kinase II (CaMKII); and heat shock pro- if any effects on the above parameters in control tein 90. No changes were found in the acute ex- rats. periments. However, on 28th day of experiment Coppey et al12 studied whether administration the amounts of GLUR1 and CaMKII were of myo-inositol could prevent the detrimental strongly reduced in the hippocampus of KA changes of motor nerve conduction velocity, en- treated animals but MI significantly halted this doneurial blood flow and endothelium-dependent reduction. Notably, in the group that received vascular relaxation of arterioles induced by ex- myo-inositol alone didn’t show change in the perimental diabetes animal model. Diabetic male amounts of studies proteins. rats of 8-9 weeks old were fed with 1% by weight of myo-inositol as a dietary supplement Chronic Studies and Carcinogenesis for a period of about 8 weeks. Administration of Liao et al18 studied the effects of myo-inositol myo-inositol completely reversed the decrease in and hexaphosphate inositol (HI) on the carcino- intracellular myo-inositol content caused by ex- genesis associated to ulcerative colitis (UC) in a perimental diabetes. Treating diabetic rats with newly developed mouse model. Female C57BL/6 myo-inositol improved the reduction of en- mice were subjected to long-term, cyclic dextran doneural blood flow and motor nerve conduction sulphate sodium (DSS) treatment and fed a 2- velocity and prevented the metabolic derange- fold iron-enriched diet. In this long-term study of ments associated with either activation of the chronic UC and associated colorectal carcino- polyol pathway or increased non-enzymatic gly- genesis, mice were randomized into six groups. cation. Myo-inositol treatment did not prevent Group 1, Group 2 and Group 3 were adminis- the gross signs of diabetes-associated toxicity, tered water, 1% inositol and 1% HI, respectively, such as decrease in body weight change, increase in the drinking water throughout the experiment in blood glucose or serum free fatty acids (FFA) as negative controls (n = 5 mice per group). and triglycerides (TG). In the myo-inositol Group 4, Group 5 and Group 6 mice were sub- group, the values of these parameters were the jected to cyclic DSS treatment. Group 4 received same as the in the diabetic untreated group. This no further treatment (positive control), whereas clearly shows that myo-inositol did cause no fur- groups 5 and 6 mice were administered 1% myo- ther functional impairment in diabetic rats. inositol or 1% HI, respectively in the drinking Solomonia et al17 investigated whether treat- fluid. The study lasted 255 days. Myo-inositol ment with myo-inositol could influence the bio- and HI did not induce any change in body weight 932 Inositol safety: clinical evidences or food consumption, both in DSS-treated and the above parameters in control or diabetic rats. untreated mice. In mice not treated with DSS, However, retinal capillary basement membrane myo-inositol or HI did not induce any change in width (CBMW) was increased significantly (ap- body weight, food consumption or mortality, as proximately 50% versus controls) after 9 months compared to negative controls receiving water. of diabetes and in the control group myo-inositol No colorectal tumors were found in mice receiv- increased CBMW to the level of untreated dia- ing Myo-inositol of HI. The colons of these mice betic rats (myo-inositol had no effect on CBMW were morphologically normal. Myo-inositol 1% in each diabetic group). The number of retinal caused a significant reduction of tumour frequen- capillaries containing pericyte nuclei and peri- cy, tumour multiplicity and tumour volume.
Load more

Recommended publications
  • Revisions to USP 31–NF 26, Second Supplement
    Revisions to USP 31–NF 26, Second Supplement (published May 2008) Published April 2008 General Chapters Monographs:A–C D–N O–S T–Z Monograph Title Section Head Scientific Liaison DANTROLENE SODIUM Dissolution <711> CAPSULES PF 33(4) Pg. 645 DEHYDROACETIC ACID PF 33(4) Title Pg. 703 DEHYDROACETIC ACID PF 33(4) Chemical Info Pg. 703 DEHYDROACETIC ACID PF 33(4) Definition Pg. 703 DEHYDROACETIC ACID PF 33(4) Packaging and storage Pg. 703 DEHYDROACETIC ACID PF 33(4) USP Reference standards <11> Pg. 703 DEHYDROACETIC ACID PF 33(4) Identification Pg. 703 DEHYDROACETIC ACID PF 33(4) Heavy Metals, Method II <231> Pg. 703 DEHYDROACETIC ACID PF 33(4) Loss on drying <731> Pg. 703 DEHYDROACETIC ACID PF 33(4) Melting range, Class I <741> Pg. 703 DEHYDROACETIC ACID PF 33(4) Residue on ignition <281> Pg. 703 DEHYDROACETIC ACID PF 33(4) Assay Pg. 703 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Title 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Definition 784 file:///C|/Documents%20and%20Settings/rwt/Desktop/revisions/usp31nf26secondSupplement03.html[4/26/2011 1:18:07 PM] DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Packaging and storage 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Labeling 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. USP Reference stadards 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Identification 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Uniformity of dosage units 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg. Loss on drying 784 DIDANOSINE TABLETS FOR ORAL SUSPENSION PF 32(3) Pg.
    [Show full text]
  • Genetic Control of Apigenin Di-C-Glycoside Biosynthesis in Bread Wheat Grain and Their Role
    Genetic control of Apigenin di-C-glycoside biosynthesis in bread wheat grain and their role as yellow pigments of Asian alkaline noodles Submitted by Grace Yasmein Wijaya This thesis is submitted to Faculty of Sciences in fulfilment of the requirements for the degree Doctor of Philosophy Faculty of Science The University of Adelaide November 2012 This book is An Answer to Prayers of a Long list of Believers I have been very blessed and loved with all of your spiritual supports, for His guidance and protections, and sincerely will not have enough to thank you all..... May you all be blessed and loved, too As I have been always, yasmein Table of Content Table of Content i List of Tables x List of Figures xiii List of Supplemental Materials xxv Summary xxx Statement of Authorship xxxiv List of Publications xxxv Acknowledgement xxxvi List of Abbreviations xxxix Chapter I: General Introduction 1 1.1 Background 1 1.2 Knowledge Gap 2 1.3 Structure of thesis 2 Chapter II: Literature review 4 2.1 Asian noodles as one of the major end-products of Australian bread wheat 4 2.2 Yellow colour of YAN 5 2.2.1 Natural Compounds that contribute to the yellow colour of YAN 5 2.2.1.1 Types of natural compounds that contributes to the yellow colour of YAN and their roles in plants and human health 5 2.2.1.2 Contribution of xanthophylls and ACGs to the yellow colour of alkaline noodles 8 2.2.2 Factors influencing the measurement of the yellowness of noodles and the content of xanthophyll and ACG in wheat grain 10 i 2.2.3 The amount, tissue location and composition
    [Show full text]
  • Tic Disorders
    No. 35 May 2012 Tic Disorders A tic is a problem in which a part of the body moves repeatedly, quickly, suddenly and uncontrollably. Tics can occur in any body part, such as the face, shoulders, hands or legs. They can be stopped voluntarily for brief periods. Sounds that are made involuntarily (such as throat clearing, sniffing) are called vocal tics. Most tics are mild and hardly noticeable. However, in some cases they are frequent and severe, and can affect many areas of a child's life. The most common tic disorder is called "transient tic disorder" and may affect up to 10 percent of children during the early school years. Teachers or others may notice the tics and wonder if the child is under stress or "nervous." Transient tics go away by themselves. Some may get worse with anxiety, tiredness, and some medications. Some tics do not go away. Tics which last one year or more are called "chronic tics." Chronic tics affect less than one percent of children and may be related to a special, more unusual tic disorder called Tourette's Disorder. Children with Tourette's Disorder have both body and vocal tics (throat clearing). Some tics disappear by early adulthood, and some continue. Children with Tourette's Disorder may also have problems with attention, and learning disabilities. They may act impulsively, and/or develop obsessions and compulsions. Sometimes people with Tourette's Disorder may blurt out obscene words, insult others, or make obscene gestures or movements. They cannot control these sounds and movements and should not be blamed for them.
    [Show full text]
  • Anxiety Disorders in Children Revised 2020
    Information about: Anxiety Disorders in Children Revised 2020 Vermont Family Network 600 Blair Park Road, Ste 240 Williston, VT 05495 1-800-800-4005 www.VermontFamilyNetwork.org Introduction According to The Child Mind Institute, “Children with anxiety disorders are overwhelmed by feelings of intense fear or worry that they are out of proportion to the situation or thing that triggers them. These emotional fears can be focused on separating from parents, physical illness, performing poorly, or embarrassing themselves. Or they can be attached to specific things, like dogs or insects or bridges.” We hope that this will give you a greater understanding of anxiety disorders and the ways that parents and professionals can support children at home, in school, and in the community. We have selected information from various sources and provided internet links when possible. The information we have presented was used by permission from various sources. We have provided links for you to find more, in-depth information at their sites. Contents Title Page Anxiety Disorders in Children and Adolescents 2 Additional Treatments and Guidance 2 The Anxious Child 3 Anxiety Quick Fact Sheet for School Personnel & 4 Parents/Guardians Children Who Won’t Go to School (Separation Anxiety) 6 Managing Anxiety with Siblings 6 Panic Disorder in Children and Adolescents 7 Parenting Tips for Anxious Kids 8 Getting Linked (local resources) 9 Advocating for Your Child: 25 Tips for Parents 10-12 Resources 13 Anxiety Disorders in Children and Adolescents What Are Anxiety Disorders? According to The National Alliance on Mental Illness (NAMI)*, “Anxiety disorders are the most common mental health concern in the United States.
    [Show full text]
  • OCD Bingo Instructions
    OCD Bingo Instructions Host Instructions: · Decide when to start and select your goal(s) · Designate a judge to announce events · Cross off events from the list below when announced Goals: · First to get any line (up, down, left, right, diagonally) · First to get any 2 lines · First to get the four corners · First to get two diagonal lines through the middle (an "X") · First to get all squares (a "coverall") Guest Instructions: · Check off events on your card as the judge announces them · If you satisfy a goal, announce "BINGO!". You've won! · The judge decides in the case of disputes This is an alphabetical list of all 29 events: Anxiety, Aviator, Brain, C.B.T., Clomipramine, Comorbidity, Compulsions, Counting, Cyclical, Hand-washing, Hepburn, History, Hughes, Indirect pathway, O.C.D., O.C.P.D., Obsessions, Persistent, Plane crash, Psychology, Recurrent, Screen Room, Scrupulosity, Stress, Tic Disorder, Washing, Y-BOCS, Zwangsneurose, phlebotomy. BuzzBuzzBingo.com · Create, Download, Print, Play, BINGO! · Copyright © 2003-2021 · All rights reserved OCD Bingo Call Sheet This is a randomized list of all 29 bingo events in square format that you can mark off in order, choose from randomly, or cut up to pull from a hat: Stress C.B.T. Hughes Hand-washing Aviator Tic Washing Obsessions O.C.D. Persistent Disorder Screen Psychology phlebotomy O.C.P.D. Scrupulosity Room Plane Compulsions Counting Zwangsneurose Comorbidity crash Clomipramine Y-BOCS Anxiety History Hepburn Indirect Cyclical Brain Recurrent pathway BuzzBuzzBingo.com · Create, Download, Print, Play, BINGO! · Copyright © 2003-2021 · All rights reserved B I N G O Screen Brain History Y-BOCS Aviator Room Zwangsneurose Hughes phlebotomy Persistent Anxiety Plane C.B.T.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Inositol (Powder) Introduced 2008
    Product Information Sheet – March 2016 Inositol (powder) Introduced 2008 What Is It? Inositol (powder) Inositol is a component of the B-complex family. It supports healthy two scoops (approximately 4.2 g) contain v central nervous system function, including emotional wellness, healthy mood and behavior. Additionally, it may promote ovarian health.* inositol (as myo-inositol) .................................................................................4.2 g serving size: approximately 4.2 g (2 scoops) Uses For Inositol (powder) servings per container: 60 Emotional Wellness: Myo-inositol is the primary form of inositol 2 scoops, 1–2 times daily, with or between meals, or as directed found in the central nervous system. It plays an important role in cell by a health professional. membrane formation and serves as part of the phosphatidylinositol second messenger system, supporting serotonin, norepinenephrine and cholinergic receptor function. As a result, inositol may support healthy mood, emotional wellness and behavior, and ease occasional nervous tension.* Ovarian Function: Research suggests that myo-inositol may help to support healthy ovulatory activity, ovarian function and reproductive system function.* What Is The Source? Myo-inositol is derived from rice bran. Recommendations Pure Encapsulations® recommends 2 scoops, 1–2 times daily, with or between meals, or as directed by a health professional. Are There Any Potential Side Effects Or Precautions? Rarely, inositol has been associated with nausea, fatigue, headache or dizziness. If pregnant or lactating, consult your physician before taking this product. Are There Any Potential Drug Interactions? At this time, there are no known adverse reactions when taken in conjunction with medications. Consult your physician for more information. *These statements have not been evaluated by the Food and Drug Administration.
    [Show full text]
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
    [Show full text]
  • Synthesis of Mannosylglucosaminylinositol
    Proc. Nati. Acad. Sci. USA Vol. 89, pp. 6025-6029, July 1992 Medical Sciences Synthesis of mannosylglucosaminylinositol phospholipids in normal but not paroxysmal nocturnal hemoglobinuria cells (complement/decay-accelerating factor/CD59) SHINICHI HIROSE*, LAKSHMESWARI RAVI*, GREGORY M. PRINCE*, MELVIN G. ROSENFELDt, ROBERT SILBERf, STEVEN W. ANDRESEN§, SANDRA V. HAZRA¶, AND M. EDWARD MEDOF*II *Institute of Pathology, Case Western Reserve University, Cleveland, OH 44106; Departments of tCell Biology and *Medicine, New York University Medical Center, New York, NY 10016; §Cleveland Clinic Foundation, Cleveland, OH 44106; and lAkron General Medical Center, Akron, OH 44307 Communicated by Frederick C. Robbins, November 29, 1991 (received for review September 12, 1991) ABSTRACT To identify mannosyl (Man)-containing inter- have been identified, information concerning the biochemical mediates ofthe human glycoinositol phospholipid (GPI) anchor pathway(s) responsible for their intracellular GPI-anchor pathway and examine their expression in paroxysmal nocturnal assembly and protein incorporation is only beginning to hemoglobinuria (PNH), mannolipid products deriving from in emerge. vitro guanosine diphosphate [3HJMan labeling of HeLa cell Among human GPI-anchored proteins are the decay- microsomes were characterized. The defined GPI species were accelerating factor (DAF) and CD59, membrane-associated correlated with products deriving from in vivo [3HJMan label- regulators of the complement cascade which protect host ing of normal and (GPI-anchor defective) affected leukocytes. tissues from autologous complement attack (reviewed in refs. In vitro analyses in HeLa cells showed dolichol-phosphoryl 2-4). Deficient expression of these proteins underlies an (Dol-P)-[3H]Man and a spectrum of [3H]Man lipids exhibiting acquired hemolytic disorder termed paroxysmal nocturnal TLC mobilities approximating those of Trypanosoma brucei hemoglobinuria (PNH), and the lesion responsible for the (Tryp) GPI precursors.
    [Show full text]
  • Ion Channels
    UC Davis UC Davis Previously Published Works Title THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Permalink https://escholarship.org/uc/item/1442g5hg Journal British journal of pharmacology, 176 Suppl 1(S1) ISSN 0007-1188 Authors Alexander, Stephen PH Mathie, Alistair Peters, John A et al. Publication Date 2019-12-01 DOI 10.1111/bph.14749 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels Stephen PH Alexander1 , Alistair Mathie2 ,JohnAPeters3 , Emma L Veale2 , Jörg Striessnig4 , Eamonn Kelly5, Jane F Armstrong6 , Elena Faccenda6 ,SimonDHarding6 ,AdamJPawson6 , Joanna L Sharman6 , Christopher Southan6 , Jamie A Davies6 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 3Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 4Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria 5School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 6Centre for Discovery Brain Science, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties.
    [Show full text]
  • Inhibition of Vessel Permeability by TNP-470 and Its Polymer Conjugate, Caplostatin
    ARTICLE Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin Ronit Satchi-Fainaro,1 Roni Mamluk,1 Ling Wang,3 Sarah M. Short,1 Janice A. Nagy,2 Dian Feng,2 Ann M. Dvorak,2 Harold F. Dvorak,2 Mark Puder,1 Debabrata Mukhopadhyay,2,3 and Judah Folkman1,* 1Children’s Hospital Boston and Harvard Medical School, Vascular Biology Program, Department of Surgery, 1 Blackfan Circle, Karp Family Research Laboratories, Floor 12, Boston, Massachusetts 02115 2 Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215 3 Biochemistry and Molecular Biology and Mayo Cancer Center, Mayo Clinic, Rochester, Minnesota 55905 *Correspondence: [email protected] Summary Angiogenesis inhibitors, such as TNP-470 and the nontoxic HPMA copolymer-TNP-470 (caplostatin), are emerging as a class of anticancer drugs. We report that TNP-470 and caplostatin inhibit vascular hyperpermeability of tumor blood vessels as well as that induced in mouse skin by different mediators. Treatment with TNP-470 or angiostatin for 3 days was sufficient to reduce permeability of tumor blood vessels, delayed-type hypersensitivity, and pulmonary edema induced by IL-2. TNP-470 also inhibited VPF/VEGF-induced phosphorylation of VEGFR-2, calcium influx, and RhoA activation in endothelial cells. These results identify an activity of TNP-470, that of inhibiting vessel hyperpermeability. This activity likely contributes to TNP-470’s antiangiogenic effect and suggests that caplostatin can be used in the treatment of cancer and inflammation. Introduction vival, and permeability) by activating VEGFR-2 (Claesson- Welsh, 2003). Angiogenesis, the generation of new blood vessels from preex- While EC proliferation is an important component of angio- isting microvasculature (Folkman and Kalluri, 2003), is regu- genesis (Koch et al., 1994), VPF/VEGF has relatively weak mi- lated by a number of different growth factors (Matsumoto and togenic activity compared to other factors such as basic fibro- Claesson-Welsh, 2001).
    [Show full text]
  • WO 2015/072853 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072853 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 45/06 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61K 31/5517 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61P 31/22 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/551 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/NL20 14/050781 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 13 November 2014 (13.1 1.2014) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 61/903,433 13 November 2013 (13.
    [Show full text]